BBP: The Biotech ETF That Filters For FDA-Approved Drugs

Cain Lee 9.17K Followers Follow Summary Virtus Biotech ETF (BBP) is rated a buy for its focused exposure to FDA-approved biotech firms and strong recent outperformance. BBP’s equal-weight, quarterly rebalancing strategy efficiently captures upside from breakout holdings like MRNA while reducing speculative risk. Rising sector deal activity and GLP-1 market expansion underpin a favorable outlook for BBP despite macro headwinds like higher interest rates. BBP’s concentrated, non-dividend-paying portfolio offers cost efficiency and resilience versus larger, broader biotech ETFs, supporting long-term positioning. Solskin/DigitalVision via Getty Images Overview Moderna, Inc. ( MRNA ) saw a massive 177% move in a single day after its personalized cancer therapy had a successful phase 3 trial. I don't typically cover healthcare stocks because there are so This article was written by Cain Lee 9.17K Followers Follow Financial analyst by day and a seasoned investor by passion, I've been involved in the world of investing for over 15 years and honed my skills in analyzing lucrative opportunities within the market.I specialize in uncovering high quality dividend stocks and other assets that offer potential for long term-growth that pack a serious punch for bill-paying potential. I use myself as an example that with a solid base of classic dividend growth stocks, sprinkling in some Business Development Companies, REITs, and Closed End Funds can be a highly efficient way to boost your investment income while still capturing a total return that follows traditional index funds. I created a hybrid system between growth and income and manage to still capture a total return that is on par with the S&P. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in BBP over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.